Prostate cancer update

Minerva Urologica e Nefrologica

Volumn 55, Issue 4, 2003, Pages 199-204

  Wilson, S S ^a   Crawford, E D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Drug therapy; Prostatic neoplasms, surgery; Prostatic neoplasms, therapy

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; AROMATASE INHIBITOR; BICALUTAMIDE; EPIRUBICIN; ESTRAMUSTINE; FINASTERIDE; GONADORELIN AGONIST; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SELENIUM; TAMOXIFEN;

BONE METASTASIS; BONE SCINTISCANNING; BREAST TENDERNESS; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; DEVELOPED COUNTRY; DIGITAL RECTAL EXAMINATION; DOSIMETRY; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; LIBIDO DISORDER; MALE; MASTALGIA; NEEDLE BIOPSY; OSTEOPENIA; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; QUALITY OF LIFE; REVIEW; SALVAGE THERAPY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION;

HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 1542288372     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. Epub 2003 Jun 24.
2. Nasr R, Goldenberg S. Rising prostate specific antigen after radical prostatectomy: a case based review. Can J Urol 2001;8:1306-13.
3. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000;164:101-5.
4. Pound C, Partin A, Epstein J, Walsh P. Prostate-specific antigen after anatomic radicalretropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
5. Akduman B, Crawford E. The management of high risk prostate cancer. J Urol 2003;169:1993-8.
6. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999;281:1598-604.
7. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
8. Coetzee LJ, Hars V, Paulson DF. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology 1996;47:232-5.
9. Johnstone PAS, Tarman G, Riffenburgh R, Rohde DC, Kane CJ. Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urol Oncol 1997;3:108-12.
10. Messing E, Manola J, Wilding G, Sarosdy M, Crawford D, Trump D. Immediate hormonal therapy vs observation for node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy: a randomised phase III Eastern Cooperative Oncology Group/Inter Group Trial. J Urol 1999;161 Suppl 175:4. (abstract 673).
11. Svetec D, McCabe K, Peretsman S, Klein E, Levin H, Optenberg S et al. Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. J Urol 1998;159:1606-8.
12. Kahn D, Haseman M, Libertino J et al. Indium-111 capromab pendetide (ProstaScint) imaging of patients with rising PSA post-prostatectomy. J Urol 1997;157:204. (abstract 795).
13. Ponsky LE, Cherullo EE, Starkey R, Nelson D, Neumann D, Zippe CD. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis 2002;5:132-5.
14. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 1996;88:166-73.
15. Do LV, Do TM, Smith R, Parker RG. Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival. Am J Clin Oncol 2002;25:1-8.
16. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-24.
17. Valicenti RK, Gomella LG, Ismail M, Strup SE, Mulholland SG, Dicker AP et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 1999;45:53-8.
18. Hudson M, Akduman B. Radiation treatment following radical retropubic prostatectomy for pathologic stage pT3N0M0 prostate cancer-long term results. J Urol 1998;159:335. (abstract 1288).
19. Schild SE, Wong WW, Grado GL, Halyard MY, Novicki DE, Swanson SK et al. The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys 1996;34:535-41.
20. Akduman B, Crawford E. The management of high risk prostate cancer. J Urol 2003;169:1993-8.
21. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000;163:845-50.
22. Nudell DM, Grossfeld GD, Weinberg VK, Roach M 3rd, Carroll PR. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 1999;54:1049-57.
23. Forman JD, Meetze K, Pontes E, Wood DP Jr, Shamsa F, Rana T et al. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol 1997;158:1436-9; discussion 1439-40.
24. Wu JJ, King SC, Montana GS, McKinstry CA, Anscher MS. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995;32:317-23.
25. Choo R, Hruby G, Hong J, Hong E, DeBoer G, Danjoux C et al. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable post-operative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys 2002;52:674-80.
26. Gheiler EL, Tefilli MV, Tiguert R, Grignon D, Cher ML, Sakr W et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 1998;51:789-95.
27. Garzotto M, Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year follow-up. J Urol 1998;159:950-4.
28. Cespedes RD, Pisters LL, von Eschenbach AC, McGuire EJ. Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients. J Urol 1997;157:237-40.
29. Perrotte P, Litwin MS, McGuire EJ, Scott SM, von Eschenbach AC, Pisters LL. Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol 1999;162:398-402.
30. De La Taille A, Hayek O, Benson MC, Bagiella E, Olsson CA, Fatal M et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology 2000;55:79-84.
31. Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53:2-10.
32. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis 1999;2:4-8.
33. Zincke H. Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology 1989;33 5 Suppl:27-36.
34. The Medical Research Council (MRC) study of the Prostate Cancer Working Party Investigators Group. Immediate vs deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79:235-46.
35. van den Ouden D, Tribukait B, Blom JH, Fossa SD, Kurth KH, ten Kate FJ et al. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1993;150(2 Pt 1):400-6.
36. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
37. Kurek R, Renneberg H, Lubben G, Kienle E, Tunn UW. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999;35 Suppl 1:27-31.
38. Bishop M. The role of anti-androgen monotherapy in the treatment of prostate cancer. BJU Int 2003;92:653-4.
39. Pummer K, Lehnert M, Stettner H, Hubmer G. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997;32 Suppl 3:81-5.
40. Schmidt J, Gibbons R, Murphy G et al. Adjuvant estramustine phosphate treatment for localized prostate cancer. PPO Updates 1997;11:1.
41. Wang J, Halford S, Rigg A, Roylance R, Lynch M, Waxman J. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000;86:675-80.